Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy-Reference-Cited by-同舟云学术

Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy

Published:2022-06 Issue:6 Volume:23 Page:e245
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Bomze David,Mutti Luciano,Goldman Adam,Markel Gal,Meirson Tomer

Publisher

Elsevier BV

Subject

Oncology

Reference5 articles.

1. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study;Diaz;Lancet Oncol,2022

2. Immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer;Bomze;JAMA Oncol,2020

3. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study;Lau;ESMO Open,2020

4. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502);Sinicrope;Proc Am Soc Clin Oncol,2019

5. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors;Galluzzi;Nat Rev Clin Oncol,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard;Pharmaceutical Statistics;2023-12-28